Related Experiment Video

Updated: Jun 13, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells

Susanne Schüler1, Petra Fritsche, Sandra Diersch

  • 1Technische Universität München, Klinikum rechts der Isar, II, Medizinische Klinik, Ismaninger Str, 22, 81675 Munich, Germany.

Molecular Cancer
|April 20, 2010
PubMed
Abstract

Insights

Targeting histone deacetylase 2 (HDAC2) sensitizes pancreatic cancer cells to TRAIL therapy by increasing receptor expression and apoptosis. This offers a new strategy to overcome treatment resistance in pancreatic ductal adenocarcinoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant cancer with poor prognosis.
  • Histone deacetylases (HDACs), particularly class I isoforms (HDAC1, 2, 3), are upregulated in PDAC.
  • Specific functions of HDAC isoenzymes in PDAC remain largely unelucidated.

Purpose of the Study:

  • To investigate the specific roles of HDAC isoenzymes in pancreatic cancer.
  • To explore strategies for overcoming resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) therapy in PDAC.

Main Methods:

  • Depletion of HDAC1 and HDAC2 in PDAC cell lines (MiaPaCa2, Panc1).
  • Treatment of cells with TRAIL and/or valproic acid (VPA), a class I HDAC inhibitor.
  • Analysis of apoptosis markers, including TRAIL receptor 1 (DR5) expression, caspase processing, and effector caspase activation.

Main Results:

  • HDAC2 depletion, not HDAC1, significantly sensitized MiaPaCa2 and Panc1 cells to TRAIL.
  • Valproic acid (VPA) synergized with TRAIL to induce apoptosis in these cell lines.
  • HDAC2 depletion led to increased DR5 expression, accelerated caspase 8 processing, enhanced Bid cleavage, and greater effector caspase activation.

Conclusions:

  • HDAC2 plays a critical role in TRAIL resistance in PDAC cells.
  • Targeting HDAC2 presents a novel therapeutic strategy to enhance TRAIL efficacy in PDAC.
  • Overcoming TRAIL resistance is crucial for successful clinical application of TRAIL-targeted therapy in PDAC.

More Related Videos

Isolated Pancreatic Islet Treatment and Apoptosis Measurement09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

Evaluating Autophagy Levels in Two Different Pancreatic Cell Models Using LC3 Immunofluorescence08:07

Evaluating Autophagy Levels in Two Different Pancreatic Cell Models Using LC3 Immunofluorescence

Published on: April 28, 2023

Related Concept Videos

Acute Pancreatitis II: Pathophysiology01:21

Acute Pancreatitis II: Pathophysiology

The pathophysiology of acute pancreatitis centers on injury to pancreatic acinar cells, which initiates a cascade of harmful intracellular events.This injury leads to premature activation of trypsinogen to trypsin in the pancreas. Trypsin then activates other digestive enzymes, such as chymotrypsin, elastase, and phospholipase A2, which begin breaking down pancreatic tissue. The resulting autodigestion causes local inflammation, tissue swelling, hemorrhage, and fat necrosis.Injured acinar cells...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...